Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449646 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1HDAC6CHRM2IMPDH2 | |
| SCHEMBL19354642 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1HDAC6CHRM2HRH3 | |
| SCHEMBL19862563 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1HDAC6CHRM2IMPDH2 | |
| SCHEMBL6177476 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL1HDAC6CHRM2HRH3 | |
| SCHEMBL24451411 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1HDAC6CHRM2HRH3 | |
| SCHEMBL2395887 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1CHRM2HRH3ALDH1A1 | |
| SCHEMBL31645911 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2ALDH1A1LMNA | |
| SCHEMBL29349628 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2ALDH1A1LMNA | |
| SCHEMBL29080 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2ALDH1A1LMNA | |
| SCHEMBL28883610 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| EP-3687540-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100130560-A1 | FUNGICIDE 2-PYRIDYL-METHYLENE-THIO CARBOXAMIDE OR 2-PYRIDYL-METHYLENE-N-SUBSTITUTED CARBOXIMIDAMIDE DERIVATIVES | BAYER SAS (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100010048-A1 | Fungicide 2-pyridyl-methylene-carboxamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | SMN1; SMN2 4089/4885L3MBTL1 4686/4885HDAC6 1234/4885 |
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CXCR4, CXCL12, CXCR1 | SMN1; SMN2 2758/4885L3MBTL1 4527/4885HDAC6 399/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | SMN1; SMN2 4292/4885L3MBTL1 4769/4885HDAC6 1116/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | SMN1; SMN2 2758/4885L3MBTL1 4527/4885HDAC6 399/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | SMN1; SMN2 3890/4885L3MBTL1 2143/4885HDAC6 363/4885 |
| US-20100010048-A1 | Fungicide 2-pyridyl-methylene-carboxamide derivatives | CYP51A1, ME2, ME3 | SMN1; SMN2 2716/4885L3MBTL1 3507/4885HDAC6 893/4885 |
| US-20100130560-A1 | FUNGICIDE 2-PYRIDYL-METHYLENE-THIO CARBOXAMIDE OR 2-PYRIDYL-METHYLENE-N-SUBSTITUTED CARBOXIMIDAMIDE DERIVATIVES | CBR3, CBR1, CNPY2 | SMN1; SMN2 3172/4885L3MBTL1 1819/4885HDAC6 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.